Bob Azelby, Eliem Therapeutics CEO

Eliem says ear­li­er drug ex­po­sure is­sues have been re­solved, drops one epilep­sy in­di­ca­tion

Af­ter be­ing forced to de­lay two Phase IIa tri­als and blam­ing CMC is­sues on a Phase Ib miss, Eliem Ther­a­peu­tics be­lieves it’s now in the clear.

The Seat­tle and UK-based biotech put out word Wednes­day morn­ing about how it con­duct­ed new ear­ly-stage stud­ies to con­firm why low ex­po­sure is­sues arose dur­ing the Phase Ib. Af­ter re­searchers com­pared the re­sults of the stud­ies, Eliem found “no mean­ing­ful dif­fer­ence” be­tween them and ruled out CMC as the rea­son for the foiled Phase Ib study, the com­pa­ny said in a press re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.